Peptide Knowledge Base · Recovery

TB-500: what it is, what the evidence says, and its real status

BPC-157's usual recovery partner, with even less human data and an extra immunogenicity question.

Can you actually get it?

Plain-English verdict: Join waitlist.

Regulatory status: PCAC recommended · rulemaking pending.

How does TB-500 work?

A synthetic 7-amino-acid fragment related to thymosin beta-4, proposed to influence actin regulation and cell migration.

What it does — and what it does not do

What it does: Researched for tendon and muscle recovery support, typically paired with BPC-157.

What it does not do: The marketed fragment is not trial-grade thymosin beta-4.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

animal-dominant; the marketed fragment isn't trial-grade thymosin β4

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Human evidence is minimal and animal-dominant; the marketed fragment differs from studied Tβ4, and antibody responses have been raised.

WADA status: Banned (S0).

How it is taken

No established human clinical dosing; research-stage only.

Who should not take it

Not characterized in humans; banned in tested sport (WADA S0). Immunogenicity of the marketed fragment is an open question.

Sources

Goldstein et al., thymosin β4 tissue-repair literature · FDA PCAC docket, Jul 2026

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.